Topical Oxybutynin 10% Gel for the Treatment of Primary Focal Hyperhidrosis: A Randomized Double-blind Placebo-controlled Split Area Study

Ofir ARTZI1, Christophoros LOIZIDES2, Eyal ZUR2 and Eli SPRECHER1,3
1Department of Dermatology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv, 2Central Compounding Laboratory, Petach-Tikva, and 3Department of Human Molecular Genetics & Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Limited efficacy, costs, side-effects and complications are issues of concern for most current therapeutic modalities for focal hyperhidrosis. This study evaluated the efficacy of topical oxybutynin 10% gel in treating 61 patients with primary focal hyperhidrosis. The gel was applied to the right or left axilla, palms or soles vs. a placebo compound to the contralateral side for 30 days. A blinded visual grading of the change in starch-iodine tests was performed by 2 non-involved physicians. The Hyperhidrosis Disease Severity Scale (HDSS) and Dermatology Life Quality Index (DLQI) questionnaires were administered before and after treatment. The patients rated their satisfaction with treatment. Fifty-three patients completed the 4-week treatment. Sweat reduction in the drug-treated sweating areas was higher than in the control-treated areas. There was a significant mean improvement in pre- and post-treatment HDSS and DLQI ($p = 0.001$ for both). Thirty-nine subjects (74%) reported moderate-to-high satisfaction. Twice-daily topical application of oxybutynin 10% gel appears to be an effective, safe and well-tolerated treatment for focal primary hyperhidrosis.

Key words: focal hyperhidrosis; axillary; palmar; plantar; topical oxybutynin.

Accepted Jun 22, 2017; Epub ahead of print Jun 27, 2017
Corr: Ofir Artzi, Department of Dermatology, Tel Aviv Medical Center, 6 Weizman Street, Tel Aviv, 6423906, Israel. E-mail: ofira@tlvmc.gov.il

Hyperhidrosis is a common condition, affecting up to 3% of the population, and has a significant impact on many aspects of the affected individual’s life (1–3). Primary hyperhidrosis manifests mainly in the axillae, palms, soles and facial regions (3). Treatment options include surgical interventions (e.g. surgical en bloc excision, liposuction or endoscopic thoracic sympathectomy) and non-surgical modalities, such as topical drugs, botulinum toxin injection, systemic drugs, iontophoresis and energy-based treatments (3). Hypohidrosis is associated with systemic anticholinergic drugs (4), which led to their use as topical agents for hyperhidrosis. For example, topical application of the anticholinergic drug glycopyrrrolate (5–10) resulted in focal improvement in sweating, although that effect may have been due in part to systemic absorption of the medication (11–13).

Oxybutynin is another anticholinergic-muscarinic receptor antagonist (14). Topical application of oxybutynin chloride gel has proved effective for the treatment of overactive bladder via transport into the circulation by passive diffusion across the stratum corneum (15). The purpose of the present study was to evaluate the efficacy of oxybutynin chloride gel 10% in the treatment of primary focal hyperhidrosis.

MATERIALS AND METHODS

This study was performed at the Tel Aviv Medical Center and approved by the Institutional Review Board. Written informed consent was obtained from all participants prior to entering the study. Sixty-one patients with confirmed primary focal hyperhidrosis who had received no topical or oral anticholinergics, iontophoresis treatment or botulinum toxin injections during the 6 months prior to study entry and had not undergone sympathectomy were recruited. Twenty-two of those 61 patients (36%) had palmar hyperhidrosis, 23 (38%) had axillary hyperhidrosis, and 16 (26%) had plantar hyperhidrosis. Demographic data, including sex, age and medical history were collected before enrolment in the study, and the following patients were excluded: pregnant or lactating women, individuals with conditions that may cause secondary hyperhidrosis, individuals with an active skin disease affecting the treated areas (e.g. eczema, seborrhoea, psoriasis), glaucoma, urinary retention, gastric retention, myasthenia gravis, angioedema, Sjögren’s syndrome, or Sicca syndrome, and candidates >60 years or <18 years of age.

The study followed a prospective, randomized, double-blind, placebo-controlled design. Each participant was given a pair of test jars (designated “gel A” and “gel B”). A designated software was used to randomize the jars (either A or B) which contained 10% oxybutynin gel or a placebo aqueous gel. The 2 jars were identical in shape, size and weight, as well as colour, odour and consistency. The patients were instructed to apply 1 cm of gel A or B on clean, dry and intact skin of one sweating area (right or left palms, soles or axillae) twice daily for 30 days. This was estimated to provide 50 mg of active oxybutynin in each application. The patients with axillary or plantar hyperhidrosis were asked to use the contralateral hand to apply the drug/placebo. The patients with palmar hyperhidrosis were instructed to use disposable transparent gloves while applying the drug/placebo. In addition, they were instructed to avoid contact of the gel with the eyes, nose, mouth, and not to wash the areas for 4 h post-application. They were also instructed not to use any concomitant topical or systemic medication during the entire treatment period. Each jar was weighed on a digital scale before treatment initiation and on the 30th day of treatment.
All patients underwent the Minor starch-iodine test (16) on the oxybutynin- and placebo-treated sides. The tested areas were photographed under standard conditions using the Galaxy Camera (3G) EK-GC100 photography system. A blinded visual grading of the photographs taken before and after 30 days of treatment was the primary endpoint. The photographs were independently assessed by 2 dermatologists who were unaware of the study design. All pairs of photographs were graded as 0 = no change, 1 = minor change of <25%, 2 = moderate change of 25–50%, 3 = major change of 50–75%, and 4 = absence or near absence of sweating.

The patients were interviewed twice; first at the time of screening before the initial application and then following completion of the 30th day of treatment. They were asked to rate the severity of their condition using the Hyperhidrosis Disease Severity Scale (HDSS) (2, 17) in which a score of 3 or 4 indicates severe hyperhidrosis, while a score of 1 or 2 indicates mild or moderate hyperhidrosis. The therapeutic results were considered as “excellent” or “good” if the patient indicated a reduction of 2 or 1 points, respectively, on the HDSS score. In addition, quality of life was assessed with the Dermatology Life Quality Index (DLQI) (2, 18) (permission by Dr A. Finlay). The word “symptomatic” was changed to “sweaty” in the first question to make it more applicable to hyperhidrosis. The DLQI is a validated 10-item questionnaire on leisure, personal relationships, daily activities, and treatment. The maximum score is 30, with 0 indicating a negligible effect of the disorder on the patient’s quality of life and 30 indicating a significant impact. A change of 0–1 points on the DLQI score was interpreted as reflecting no effect on the patient’s life, a change of 2–5 points as a small effect, 6–10 points as a moderate effect, 11–20 points as a very significant modification, and 21–30 points as the most significant impact possible.

At the end of the treatment, patients completed a questionnaire evaluating the following: (i) sweat reduction in the treated and in the control sweating areas (0 = no change, 1 = poor (limited improvement with the patient being very much aware of sweating), 2 = fair (marked improvement, with noticeable sweating under stressful conditions only), 3 = good (marked improvement with minimal sweating under stressful conditions), and 4 = excellent improvement, with cessation of sweating). (ii) Global patient satisfaction (0 = dissatisfied, 1 = partially satisfied, 2 = satisfied, and 3 = highly satisfied). (iii) Side-effects: dry mouth, headache, dizziness, urine retention, constipation and application site reactions (pruritus or dermatitis).

Both the study and control gels were compounded in an Israeli compounding pharmacy. The composition of the study gel was as follows: oxybutynin chloride 10% (active gel) dissolved in ethanol 95%, glycerin, tween-80, medium chain triglycerides oil, apple scent and hypromellose gel. The placebo gel contained the same ingredients excluding oxybutynin chloride.

Continuous variables were fed into a tabular format as means ± standard errors and compared using the Wilcoxon paired test. Categorical variables were tested using the Fisher’s exact test. Correlation between raters was evaluated using Spearman’s correlation. The level of significance was defined as α = 0.05. All analyses were carried out using SPSS 23.0.2.

RESULTS

Twenty of the 22 patients with palmar hyperhidrosis, 21 of the 23 patients with axillary hyperhidrosis, and 12 of the 16 patients with plantar hyperhidrosis completed the 4 weeks of treatment. Forty-one patients (77%) were female and 12 patients (23%) were male. The mean ± SD age of patients ranged from 18 to 52 years (31.6 ± 1.4 years). They reported having hyperhidrosis for 1.5 to 40 years (15.2 ± 1.4 years). Thirty-six patients (67.9%) had never been treated for their condition, 6 (11.3%) had tried several topical anti-perspirants with variable efficacy, and 11 (20.8%) had undergone effective treatment with botulinum toxin injections.

No serious systemic side-effects were encountered during the study period. Two patients reported transient headaches in the first week of treatment. Eleven of the 23 patients with axillary hyperhidrosis reported erythema and pruritus upon applying the study gel. Instructing those patients to wait 2 days between shaving and first use as well as application of the gel on a clean and dry skin at room temperature attenuated these side-effects. Eight of the 16 patients with plantar hyperhidrosis reported that the product was “sticky” and unpleasant to use. A total of 8 patients withdrew from the study for the following reasons: 2 due to time constraints, 2 due to recurrent erythema and itching, and 4 who reported that the product was “sticky” and inconvenient to use. The mean ± standard deviation (SD) consumption per application of the studied material (oxybutynin containing gel) was 41 ± 9.98 mg.

Photographic comparisons (Fig. 1) of the Minor starch-iodine test results before and after 30 days of treatment were blindly evaluated by 2 independent raters. The raters’ evaluations were highly concordant for both the treated and control sides ($r_{s,x} = 0.83, p < 0.001$ and...
The mean score for axillary hyperhidrosis in the study gel sweating areas was 3.4 ± 0.2 compared with the control sweating areas (2.5 ± 0.3, *p* = 0.002). The mean score for palmar hyperhidrosis in the study gel sweating areas was 3.1 ± 0.2 compared with the control sweating areas (1.4 ± 0.3, *p* = 0.001). The mean score for plantar hyperhidrosis in the study gel sweating areas was 2.9 ± 0.4 compared with the control gel sweating areas (1.9 ± 0.4, *p* = 0.007). At the end of the study, 42 out of 53 patients (79%) correctly indicated the side that had been treated by active oxybutynin gel. The patients’ grades for sweat reduction in the drug-treated sweating areas vs. the control-treated sweating areas are shown in **Fig. 2**. The mean sweat reduction was 2.49 ± 0.1 for the drug-treated area and 1.53 ± 0.1 for the control-treated area (*p* < 0.001).

A change in perspiration was noted in the treated and control areas as well as in other distant sites (face, back). The changes as reported in the HDSS score are shown in **Fig. 3**. Most of the patients (66%) reported a 1-point reduction in their HDSS score. The mean DLQI before treatment was 14.9 ± 0.8 (palmar 13.7 ± 1.2, plantar 16.4 ± 2.0, and axilla 15.1 ± 1.4). At the end of the treatment period, the mean post-treatment DLQI was 7.3 ± 0.6 (palmar 6.9 ± 0.9, plantar 8.2 ± 1.4, and axilla 7.2 ± 0.8, *p* < 0.003) (**Fig. 4**). Out of the 53 patients who completed the study, 5 (9.4%) reported no change in DLQI, 15 (28.3%) reported a small effect, 18 (34%) reported a moderate effect, and 15 (28.3%) reported a large effect. The change was most noticeable among patients with axillary hyperhidrosis (**Fig. 5**). Thirty-nine subjects (74%) were moderately to highly satisfied. The degree of satisfaction for the different treated areas is shown in **Fig 6**.

**DISCUSSION**

Hyperhidrosis is defined as excessive sweating beyond normal thermoregulatory needs and environmental conditions. It is a relatively common disorder, with a prevalence of 3% in the US (1), and one that significantly impairs the affected individual’s quality of life (2, 3). Treatment of primary focal hyperhidrosis remains challenging. The use of topical agents that occlude sweat ducts, such as aluminium chloride, formaldehyde, glutaraldehyde and potassium permanganate preparations, is limited by short-term effect, limited efficacy and irritation (19–21). The use of oral anticholinergics is associated with systemic adverse effects (4, 22–25). Other oral medications, such as diazepam (25) and clonidine (26, 27), are limited by their neurocardiovascular side-effects. Iontophoresis for the treatment of palmar and plantar hyperhidrosis is time-consuming (3, 28) and

![Fig. 2. Primary focal hyperhidrosis. Patients’ grade for sweat reduction in the drug-treated compared with the control-treated sweating areas.](image1)

![Fig. 4. Primary focal hyperhidrosis. The Dermatology Life Quality Index (DLQI) ratings at baseline and following 30 days of twice daily application of 10% oxybutynin gel.](image2)

![Fig. 5. Primary focal hyperhidrosis. Changes in the Dermatology Life Quality Index (DLQI) ratings following 30 days of twice daily application of 10% oxybutynin gel.](image3)
might cause several side-effects, ranging from tingling and erythema to painful stinging, itching, blistering and mild electric shock sensations. Injections of botulinum toxin (29–31) for axillary, palmar or plantar hyperhidrosis is efficacious, but entails high costs and pain, in addition to its being potentially linked to possible neurologic side-effects. Surgical procedures (surgical en bloc excision, liposuction or endoscopic thoracic sympathectomy) offer a permanent solution, but are associated with significant and sometimes irreversible side-effects (32–35). Laser- (36–38), radiofrequency thermotherapy- (39), and microwave- (40–43) based therapies have been suggested recently as possible treatment modalities, but data on their long-term efficacy, safety and side-effects are still lacking.

The ideal treatment for primary hyperhidrosis should be one that is simple and non-invasive, with few complications and a low financial burden. Topical anticholinergic agents, such as glycopyrrolate, have had inconsistent efficacy in improving sweating (5–10) and were more effective for the sweating of the craniofacial area than other areas (7). Their effect may be partly systemic due to transdermal absorption and distant effect (11–13). Although many systemic anticholinergic adverse effects (dry mouth, blurry vision, constipation, difficulty in urinating, cognitive and memory impairments) can be attributed to oxybutynin, which is another cholinergic-muscarinic receptor antagonist, several peer-reviewed articles that included long-term use reported high levels of safety for its treatment of various pathologies, especially when used orally in low and incremental doses or topically (14, 44–49). Topical application of oxybutynin chloride gel is indicated for the treatment of overactive bladder where its effect is due to systemic absorption (15).

The current study evaluated a topical formulation of oxybutynin for the treatment of primary localized axillary, palmar or plantar hyperhidrosis. We found that a twice daily application of 10% topical oxybutynin gel resulted in a significant reduction in HDSS scores and a significant improvement in DLQI scores, as well as being associated with a high rate of patient satisfaction. Objective assessment by means of the Minor starch-iodine assay corroborated the subjective data collected from the patients. Of note, despite the drug having been applied in only one area, the control areas showed improvement according to the assessment of the 2 raters, a finding that could be attributed to the passive diffusion of the gel across the stratum corneum and its systemic absorption.

In conclusion, the present data demonstrated that topical oxybutynin appears to be a safe and efficient therapeutic option for focal primary hyperhidrosis. Follow-up studies are needed to measure the extent of drug absorption as well as to optimize dosage and improve drug formulation.

ACKNOWLEDGEMENTS

The authors acknowledge Ms Dvora Cohen, Ms Shimrit Tradion and Shoshi Zilber for their assistance in patient recruitment. Esther Eshkol is thanked for editorial assistance.

Conflicts of interest: At the time of study, E. Zur was the compounding pharmacist and scientific manager of the compounding pharmacy that manufactured the topical gels for the trial. However, he was not involved in the trial operation and declares no conflict of interest.

REFERENCES

13. Panting KJ, Alkali AS, Newman WD, Sharpe GR. Dilated pu-
pils caused by topical glycopyrrolate for hyperhidrosis. Br J
MA, BiscegiJatene F, et al. The use of oxybutynin for treating
15. Staskin DR, Dmochowski RR, Sand PK, Macdiarmid SA, Car-
melli KE, Thomas H, et al. Efficacy and safety of oxybutynin
chloride topical gel for treatment of adults with overactive
bladder: a randomized, double-blind, placebo-controlled,
Recommendations for performing and evaluating the results of
the minor test according to a sweating intensity visual
17. Varella AY, Fukuda JM, Teivelis MP, Campos JR, Kauffman
P, Cucato GG, et al. Translation and validation of Hyperhi-
drosis Disease Severity Scale. Rev Assoc Med Bras 2016;
18. Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin
M, et al; Canadian Hyperhidrosis Advisory Committee. A
comprehensive approach to the recognition, diagnosis, and
severity-based treatment of focal hyperhidrosis: recommen-
dations of the Canadian Hyperhidrosis Advisory Committee.
19. Juhlin L, Hansson H. Topical glutaraldehyde for plantar hy-
20. Gordon BJ, Maibach HI. Eccrine anhidrosis due to glutar-
aldehyde, formaldehyde, and iontophoresis. J Invest Dermat
21. Jensen O, Karlmark T. Palmpoplar hyperhidrosis. Treat-
ment with alcohol solution of aluminium chloride hexa-
hydrate: a simple method of transpiration measurement.
Dermatologica 1980; 161: 133–135.
22. Paller AS, Shah PR, Silverio AM, Wagner A, Chamilin SL, Man-
cini AJ. Oral glycopyrrolate as second-line treatment for
67: 918–923.
23. Kumar MG, Foreman RS, Berk DR, Bayliss SJ. Oral glycopyr-
rolate for refractory pediatric and adolescent hyperhidrosis.
advances and new therapeutic options for primary hyperhi-
Psychiatry 1995; 56: 35.
27. Torch EM. Remission of facial and scalp hyperhidrosis with
clonidine hydrochloride and topical aluminum chloride. South
28. Nyamekye IK. Current therapeutic options for treating pri-
mary hyperhidrosis. Eur J Vasc Endovasc Surg 2004; 27:
571–576.
29. Kreyden OP, Scheidegger EP. Anatomy of the sweat glands,
pharmacology of botulinum toxin, and distinctive syndro-
22: 40–44.
30. Glaser DA, Hebert AA, Pariser DM, Solish N. Palmar and
plantar hyperhidrosis: best practice recommendations and
31. Doft MA, Hardy KL, Asherman JA. Treatment of hyperhidrosis
32. Doolabh N, Horswell S, Williams M, Huber L, Prince S, Meyer
DM, et al. Thoracoscopic sympathectomy for hyperhidrosis:
33. Kravarusis D, Freud E. Thoracoscopic sympathectomy gang-
iablation in the management of palmer hyperhidrosis: a
decade experience in a single institution. Afr J Paediatr Surg
34. Steiner Z, Cohen Z, Kleinor O, Matar I, Mogilner J. Do children
tolerate thoracoscopic sympathectomy better than adults?
35. Ojimba TA, Cameron AE. Drawbacks of endoscopic thoracic
36. Letada PR, Landers JT, Uebelhoer NS, Shumaker PR. Tre-
atment of focal axillary hyperhidrosis using a long pulsed
Nd: YAG 1064 nm laser at hair reduction settings. J Drugs
Reversibility of hyperhidrosis post axillary depilatory laser.
38. Bechara FG, Georgas D, Sand M, Stucker M, Othlinghaus
N, Altmeier P, et al. Effects of a long-pulsed 800-nm diode
laser on axillary hyperhidrosis: a randomized controlled half-
39. Schick CH, Grallath T, Schick KS, Hashmonai M. Radiofre-
quency thermotheraphy for treating axillary hyperhidrosis.
40. Hong HC, Lupin M, O’Shaughnessy KF. Clinical evaluation
of a microwave device for treating axillary hyperhidrosis.
41. Lee S, Chang K, Suh D, Song KY, Ryu HJ. The efficacy of
a microwave device for treating axillary hyperhidrosis and
42. Glaser DA, Coleman WP, Fan LK, Kaminer MS, Kilmer SL, Nos-
ra S, et al. A randomized, blinded clinical evaluation of a
novel microwave device for treating axillary hyperhidrosis:
the dermatologic reduction in underarm perspiration study.
43. Jacob C. Treatment of hyperhidrosis with microwave tech-
44. Wolosker N, Schvartsman C, Krutman M, Campbell TP, Kauff-
outcomes of oxybutynin for treating palmar hyperhidrosis
in children younger than 14 years old. Pediad Dermatol
2014; 31: 48–53.
45. Teivelis MP, Wolosker N, Krutman M, Kauffman P, Campos
JR, Puech-Léao P. Treatment of uncommon sites of focal
primary hyperhidrosis: experience with pharmacological
therapy using oxybutynin. Clinics (Sao Paulo) 2014; 69:
608–614.
46. Schollhammer M, Brenaut E, Menard-Andivout N, Pillette-
as a treatment for generalized hyperhidrosis: a randomi-
ized, placebo-controlled trial. Br J Dermatol 2015; 173:
1163–1168.
47. Wolosker N, Teivelis MP, Krutman M, de Paula RP, Kauffman
P, de Campos JR, et al. Long-term results of the use of oxy-
butynin for the treatment of axillary hyperhidrosis. Ann Vasc
48. Cartwright PC, Coplen DE, Kogan BA, Volinn W, Finan E, Hoel
G. Efficacy and safety of transdermal and oral oxybutynin in
182: 1548–1554.
M, et al. Differential effects of the antimuscarinic agents
darifenacin and oxybutynin ER on memory in older subjects.